Atea Pharmaceuticals (AVIR) Interest Expenses (2019 - 2026)

Atea Pharmaceuticals' Interest Expenses history runs 8 years deep, the most recent figure standing at $26.6 million for Q1 2026.

• On a quarterly basis, Interest Expenses rose 444.85% year-over-year to $26.6 million in Q1 2026; TTM through Mar 2026 was $26.6 million, a 444.85% increase from a year earlier, with the FY2025 full-year figure at $8.4 million, down 92.8% from the prior year.
• Interest Expenses advanced to $26.6 million in Q1 2026 per AVIR's latest filing, from $44000.0 in the prior quarter.
• Across five years, Interest Expenses topped out at $26.6 million in Q1 2026 and bottomed at $44000.0 in Q4 2025.
• The 5-year median for Interest Expenses is $394000.0 (2023), against an average of $4.2 million.
• Across the five-year window, Interest Expenses soared 4964.95% in 2023 and tumbled 42.99% in 2025, its largest moves.
• Year by year, Interest Expenses stood at $78000.0 in 2022, then slipped by 15.38% to $66000.0 in 2023, then gained by 16.67% to $77000.0 in 2024, then tumbled by 42.86% to $44000.0 in 2025, then soared by 60340.91% to $26.6 million in 2026.
• Per Business Quant, the three latest AVIR Interest Expenses figures stand at $26.6 million (Q1 2026), $44000.0 (Q4 2025), and $4.6 million (Q3 2025).